Friday, December 4th: 1:30 – 3:30 pm
The use of biomarkers in cardiovascular medicine is fraught with controversy. While clinicians and trialists may desire greater reliance on biomarkers, regulatory bodies are less enthusiastic about these surrogate endpoints. This session is chaired by Dr. Lawrence Fine, a Program Officer for Prevention of Hypertension at the National Heart, Lung, and Blood Institute, and Dr. Kirkwood Adams, an active clinical researcher of congestive heart failure from the University of North Carolina.
Cardiologists are constantly working to define the optimal use of biomarkers. Join this session to learn more about the current state-of-the-art, and expert attitudes around some key questions. What is the value of biomarkers in primary prevention trials? While some would argue that they should only be used for population risk enrichment, others insist they are useful surrogates for efficacy. How can imaging enhance clinical trials of the future? What biomarker strategies can be used to improve clinical management? How can we hasten the incorporation of precision medicine into heart failure management? What is the optimal use of hs-Troponin in ischemic syndromes, and biomarkers in atrial fibrillation?
Other speakers include Dan Levy (Boston, USA), Charalambos Antoniades (Oxford, GBR), Sandra Sanders-van Wijk (Maastricht, NED), Christopher De Filippi (Washington, USA), and Ziad Hijazi (Uppsala, SWE), with industry viewpoints provided by Agim Beshiri (Abbott Dx, USA), Karine Santos (Sphingotec, GER). The moderated multi-stakeholder expert panel for this session promises to be lively, with experts from all areas discussing the future of CV biomarker clinical development in 2021.